Skip to main content

Table 1 Clinical and pathological characteristics of the 63 patients treated with anti-PD-1 plus chemotherapy

From: Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer

Characteristics

 

Number

Percent

Age, mean (SD)

 

52.3 (12.7)

 

Gender

Male

36

57.1%

 

Female

27

42.9%

ECOG PS

0

44

69.8%

 

1 ~ 2

19

30.2%

BMI, mean (SD)

 

21.3 (2.94)

 

Tumor location

GEJ

15

23.8%

 

Stomach

48

76.2%

Tumor differentiation

Well-moderate

6

9.5%

 

Poor

51

81.0%

 

Unknown

6

9.5%

Number of organs with metastasis, median (IQR)

 

2 (1–2)

 

Lines of anti-PD-1 therapy

First line

36

57.1%

 

Second line or later

27

42.9%

Cycles of anti-PD-1 therapy, median (IQR)

 

5 (4–8)

 

HER2 status

Positive

12

19.0%

 

Negative

51

81.0%

PD-L1 expression

CPS ≥ 1

50

79.4%

 

CPS < 1

13

20.6%

MMR status

pMMR

53

84.1%

 

dMMR

4

6.3%

 

Unknown

6

9.5%

EBV status

Positive

4

6.3%

 

Negative

51

81.0%

 

Unknown

8

12.7%

Disease response (RECIST 1.1)

CR

8

12.7%

 

PR

23

36.5%

 

SD

18

28.6%

 

PD

14

22.2%

NLR, mean (SD)

 

3.56 (2.71)

 

LMR, mean (SD)

 

3.62 (3.96)

 
  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, BMI Body mass index, GEJ gastroesophageal junction, IQR interquartile range, PD-1 programmed death-1, HER2 human epidermal growth factor receptor-2, PD-L1 programmed death ligand 1, CPS combined positive score, MMR mismatch repair, pMMR proficient mismatch repair, dMMR deficient mismatch repair, EBV Epstein-Barr Virus, CR complete response, PR partial response, SD stable disease, PD progression disease, NLR neutrophil-to-lymphocyte ratio, LMR lymphocyte-to-monocyte ratio